Zydus Lifesciences (ZYDUSLIFE) Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
ZYDUSLIFE Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Zydus Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹915.40 |
| 52 Week High | ₹1,059.05 |
| 52 Week Low | ₹813.00 |
| Beta | 0.39 |
| 1 Month Change | 1.05% |
| 3 Month Change | 1.63% |
| 1 Year Change | 5.36% |
| 3 Year Change | 82.31% |
| 5 Year Change | 73.65% |
| Change since IPO | 10,450.24% |
Recent News & Updates
Recent updates
Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Feb 09
There Is A Reason Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Price Is Undemanding
Jan 22Is Zydus Lifesciences (NSE:ZYDUSLIFE) Using Too Much Debt?
Nov 29Analysts Are Updating Their Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Estimates After Its Second-Quarter Results
Nov 09Are Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Investors Paying Above The Intrinsic Value?
Sep 15There's No Escaping Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Muted Earnings
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 15Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 06Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹11.00
Jul 22Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jul 06Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Larger Dividend Than Last Year At ₹11.00
Jun 22Zydus Lifesciences (NSE:ZYDUSLIFE) Is Paying Out A Larger Dividend Than Last Year
May 23
Innovation In Healthcare And Wellness Propels This Company's Global Growth Journey
Focus on innovation and differentiated products in India and international markets aims to drive revenue and enhance net margins.Shareholder Returns
| ZYDUSLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.7% | 2.7% | 6.9% |
| 1Y | 5.4% | 5.1% | 7.0% |
Return vs Industry: ZYDUSLIFE matched the Indian Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: ZYDUSLIFE underperformed the Indian Market which returned 7% over the past year.
Price Volatility
| ZYDUSLIFE volatility | |
|---|---|
| ZYDUSLIFE Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: ZYDUSLIFE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ZYDUSLIFE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 27,917 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands.
Zydus Lifesciences Limited Fundamentals Summary
| ZYDUSLIFE fundamental statistics | |
|---|---|
| Market cap | ₹921.11b |
| Earnings (TTM) | ₹49.38b |
| Revenue (TTM) | ₹260.89b |
Is ZYDUSLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYDUSLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹260.89b |
| Cost of Revenue | ₹72.14b |
| Gross Profit | ₹188.76b |
| Other Expenses | ₹139.37b |
| Earnings | ₹49.38b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 30, 2026
| Earnings per share (EPS) | 49.08 |
| Gross Margin | 72.35% |
| Net Profit Margin | 18.93% |
| Debt/Equity Ratio | 34.3% |
How did ZYDUSLIFE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 09:01 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zydus Lifesciences Limited is covered by 62 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |